Engineered AAV Vectors for CNS Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering genes to the central nervous system (CNS) are inefficient, particularly in targeting neural cells widely distributed in the CNS, and there is a lack of effective strategies for regenerating damaged CNS axons, which are crucial for treating neurological diseases such as Alzheimer's, Parkinson's, and traumatic brain injury.
Innovation Solution
Development of an engineered adeno-associated viral (AAV) vector with modified capsid proteins and a neural cell-specific promoter, encoding inhibitors of neural anti-regenerative pathways, such as let-7 miRNA and CSPG receptors, to enhance gene delivery and promote axon regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Area of stationary object
If AAV vectors are administered systemically to target CNS cells, then the ability to reach widely distributed neural cells is improved, but the blood-brain barrier prevents efficient transduction
Solution Approach 1:
The patent applies local quality by engineering specific regions of the AAV capsid protein with targeted mutations and peptide insertions. These localized modifications at specific capsid surfaces enhance BBB penetration capability while preserving other functional regions, thereby achieving both wide CNS coverage and reliable transduction efficacy simultaneously
Solution Approach 2:
The patent changes physical-chemical parameters of the AAV capsid through engineered mutations and peptide insertions. These parameter changes in capsid structure and surface properties enable the vector to overcome the blood-brain barrier while maintaining high transduction efficiency in target neural cells
2Reliability
If invasive injection methods are used to deliver viral vectors, then regional gene delivery is achieved, but the ability to target widely distributed neural cells is insufficient
Solution Approach 1:
The patent applies universality by designing an AAV vector system that can perform multiple functions: it maintains the precision of regional delivery through targeted injection while simultaneously achieving wide CNS distribution through engineered BBB-penetrating capsids. This multi-functional design allows a single vector to address both localized and distributed gene delivery needs
3Reliability
If engineered AAV9 capsids are used to enhance BBB crossing, then transduction in some CNS regions is improved, but overall transgene expression levels remain low
Solution Approach 1:
The patent applies composite materials by creating an engineered AAV capsid that combines multiple functional elements: the AAV9 base structure with specific mutations and peptide insertions. This composite capsid design integrates BBB-penetrating capabilities with enhanced transduction efficiency, resulting in both improved BBB crossing and higher overall transgene expression levels across multiple CNS regions
Data Source
AI summary
The present invention generally relates to engineered adeno-associated viral (AAV) vectors capable of traversing the blood-brain barrier and transducing specific neural cells with high efficiency. The present invention also relates to methods of producing engineered AAV vectors and treating diseases and disorders associated with neural cell damage and degeneration.